JPRN-jRCT2051220003招募中3 期
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)
Tanaka Tomoyuki0 个研究点目标入组 224 人开始时间: 2022年4月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 224
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Patients will be male and female with primary ITP with duration of >6 months in pediatric participants aged 12 to <18 years (pediatric participants aged 10 to <12 years will be enrolled in the EU [EEA countries] only) and duration of >3 months in ages 18 years and above
- •2. Patients who had a response (achievement of platelet count >= 50,000/microL) to IVIg/anti-D or CSs that was not sustained and who have documented intolerance, insufficient response or any contra-indication to any appropriate courses of standard of care ITP therapy
- •3. An average of 2 platelet counts at least 5 days apart of <30,000/microL during the Screening period and no single platelet count >35,000/microL within 14 days prior to the first dose of study drug
- •- Pediatric patients must additionally be determined to need treatment for ITP as per clinical assessment by the Investigator
- •4. Adequate hematologic, hepatic, and renal function (absolute neutrophil count >= 1.5 X 10^9/L, AST/ALT <= 1.5 x upper limit of normal [ULN], albumin >= 3 g/dL, total bilirubin <= 1.5 x ULN [unless the patient has documented Gilbert syndrome], glomerular filtration rate >50 [Cockcroft and Gault method])
- •5. Hemoglobin >9 g/dL within 1 week prior to Study Day 1
- •6. All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •7. Patients must be able to provide written informed consent or informed assent with corresponding informed consent obtained from the patient's guardian and agree to the schedule of assessments
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •1. Patients with secondary ITP
- •2. Pregnant or lactating women
- •3. History (within 5 years of Study Day 1) or current, active malignancy requiring or likely to require chemotherapeutic or surgical treatment during the study, with the exception of non melanoma skin cancer
- •4. Transfusion with blood, blood products, plasmapheresis, or use of any other rescue medications with intent to increase platelet count within 14 days before Study Day 1
- •5. Change in CS and/or TPO-RA dose within 14 days prior to Study Day 1 (more than 10% variation from current doses)
- •6. Immunosuppressant drugs other than CSs within 5 times the elimination half-life of the drug or 14 days of Study Day 1, whichever is longer
- •7. Treatment with rituximab or splenectomy within the 3 months prior to Study Day 1
- •- Patients treated with rituximab will have normal B-cell counts prior to enrollment
- •8. Has received any investigational drug within the 30 days before receiving the first dose of study medication, or at least 5 times elimination half-life of the drug (whichever is longer); patient should not be using an investigational device at the time of dosing
- •- Patients who previously received treatment with Bruton's Tyrosine Kinase (BTK) inhibitors (except rilzabrutinib) within 30 days before the first dose of study drug are not eligible
- •- Patients who previously received rilzabrutinib at any time are not eligible
- •9. History of solid organ transplant
- •10. Myelodysplastic syndrome
- •11. Live vaccine within 28 days prior to Study Day 1 or plan to receive one during the study
- •12. Planned surgery in the time frame of the dosing period
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents who are Hospitalized due to Serious Influenza.MedDRA version: 14.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsInfluenzaEUCTR2009-012367-34-BGBioCryst Pharmaceuticals, Inc.600
招募中
1 期
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-004294-14-NOCelgene International II Sàrl485
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Active Crohn's Diseasemoderately to severely active Crohn’s diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2018-004614-18-HUEli Lilly and Company1,150
进行中（未招募）
1 期
The study of an investigational drug, Cenicriviroc, for the treatment of liver fibrosis in patients with Nonalcoholic Steatohepatitis (NASH).iver fibrosis in Subjects with Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-004566-26-BETobira Therapeutics Inc., a subsidiary of Allergan plc2,000
进行中（未招募）
1 期
A Phase 3 Study in Moderate to Severe Chronic Psoriasis PatientsMedDRA version: 20.0 Level: LLT Classification code 10071117 Term: Plaque psoriasis System Organ Class: 100000004858Plaque PsoriasisEUCTR2014-003492-36-BGCB Biopharma, SPR561